Search results
Showing 91 to 105 of 114 results for rheumatoid arthritis
Nirmatrelvir plus ritonavir and tocilizumab for treating COVID-19 (TA878)
Evidence-based recommendations on nirmatrelvir plus ritonavir (Paxlovid) and tocilizumab (RoActemra) for treating COVID-19.
Therapeutic monitoring of TNF-alpha inhibitors in rheumatoid arthritis (DG36)
We have moved Diagnostics guidance 36 to become HealthTech guidance 521. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.
NICE has developed a medtech innovation briefing (MIB) on Mobi-C for cervical disc replacement
Cox-II inhibitors for the treatment of osteoarthritis and rheumatoid arthritis (TA27)
This guidance has been replaced by NICE guideline CG59 and NICE guideline CG79.
The clinical effectiveness and cost effectiveness of anakinra for rheumatoid arthritis (TA72)
This appraisal has been updated and replaced by NICE guideline CG79.
This guidance has been updated and replaced by NICE technology appraisal guidance 375.
Evidence-based recommendations on baricitinib (Olumiant) for treating severe alopecia areata in adults.
Topical antimicrobial dressings for locally infected leg ulcers: late-stage assessment (HTG751)
Late stage assessment (LSA) guidance on topical antimicrobial dressings for locally infected leg ulcers.
View recommendations for HTG751Show all sections
Evidence-based recommendations on automated ankle brachial pressure index measurement devices to detect peripheral arterial disease in people with leg ulcers.
In development Reference number: GID-TA11352 Expected publication date: TBC
NICE has developed a Medtech Innovation Briefing (MIB) on the OSCAR 3 ultrasonic arthroplasty revision instrument for removing bone cement during prosthetic
This guidance has been updated and replaced by NICE technology appraisal guidance 375.
This guidance has been updated and replaced by NICE technology appraisal guidance 280.
Evidence-based recommendations on pembrolizumab (Keytruda) for treating metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency in adults.